Nevertheless, CEA testing can yield false positives due to benign conditions and has limited sensitivity for early‐stage disease detection, underscoring the pressing need for improved diagnostic methods and blood biomarkers to enhance CRC detection. The gene discussed is CEACAM5; the disease is colorectal carcinoma.